<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00780000</url>
  </required_header>
  <id_info>
    <org_study_id>CA201-002</org_study_id>
    <secondary_id>2007-003121-25</secondary_id>
    <secondary_id>KDG-201</secondary_id>
    <nct_id>NCT00780000</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer</brief_title>
  <official_title>Phase 2 Clinical Trial of Intravenous Alvespimycin [KOS-1022] in Patients With Her2 Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the anti-tumor activity (via objective response
      rate) of alvespimycin in patients with breast cancer who have not previously received
      trastuzumab (except as adjuvant therapy).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective tumor response rate (either RECIST or WHO complete response, partial response or minor response) confirmed by CT and MRI as the preferred methods for tumor assessments and Chest x-ray is acceptable for pulmonary lesions</measure>
    <time_frame>Within 28 days prior to the start of treatment with tumor assessments reevaluated every 8 weeks (+/- 4 days)</time_frame>
    <description>(all patients were off study by June 2008)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events assessed according to the NCI CTCAE (v 3.0) grading system</measure>
    <time_frame>Within 28 days prior to the start of treatment, and for 167 days</time_frame>
    <description>(all patients were off study by June 2008)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory tests assessed according to the NCI CTCAE (v 3.0) grading system</measure>
    <time_frame>Within 10 days prior to Cycle 1/1st infusion; within 48 hours of infusion (Cycle 1/Weeks 2/3/4 and Cycle 2+/Week3), or within 72 hours prior to infusion (Cycle 2+/Week 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Within 28 days prior to the start of treatment, Day1 of Weeks 1, 2, and 3 of Cycle 1 (4 weeks long), and prior to each 4-week cycle starting with Cycle 2, for 167 days</time_frame>
    <description>(all patients were off study by June 2008)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karnofsky Performance Status</measure>
    <time_frame>Within 28 days prior to the start of treatment, prior to each 4-week cycle starting with Cycle 2, for 167 days</time_frame>
    <description>(all patients were off study by June 2008)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular testing</measure>
    <time_frame>Within 28 days prior to the start of treatment, Cycle 1/Day 10 (3 days +/- 1 day following the 2nd infusion in the first cycle of therapy), prior to Cycle 2, if clinically indicated thereafter, for 167 days</time_frame>
    <description>(all patients were off study by June 2008)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier estimate of time to progression</measure>
    <time_frame>Within 28 days prior to the start of treatment with tumor assessments reevaluated every 8 weeks (+/- 4 days)</time_frame>
    <description>(all patients were off study by June 2008)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression on the patient's prior cytotoxic chemotherapy compared to the patient's time to progression on alvespimycin</measure>
    <time_frame>Within 28 days prior to the start of treatment with tumor assessments reevaluated every 8 weeks (+/- 4 days)</time_frame>
    <description>(all patients were off study by June 2008)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier estimate of progression-free survival</measure>
    <time_frame>Within 28 days prior to the start of treatment with tumor assessments reevaluated every 8 weeks (+/- 4 days)</time_frame>
    <description>(all patients were off study by June 2008)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier estimate of time to response</measure>
    <time_frame>Within 28 days prior to the start of treatment with tumor assessments reevaluated every 8 weeks (+/- 4 days)</time_frame>
    <description>(all patients were off study by June 2008)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier estimate of duration of response</measure>
    <time_frame>Within 28 days prior to the start of treatment with tumor assessments reevaluated every 8 weeks (+/- 4 days)</time_frame>
    <description>(all patients were off study by June 2008)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier estimate of time to treatment failure</measure>
    <time_frame>Within 28 days prior to the start of treatment with tumor assessments reevaluated every 8 weeks (+/- 4 days)</time_frame>
    <description>(all patients were off study by June 2008)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier estimate of overall survival</measure>
    <time_frame>Within 28 days prior to the start of treatment with tumor assessments reevaluated every 8 weeks (+/- 4 days)</time_frame>
    <description>(all patients were off study by June 2008)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in tumor markers</measure>
    <time_frame>Within 28 days prior to the start of treatment, Prior to each 4-week cycle starting with Cycle 2, for 167 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathological and molecular profile of responding and non-responding patients using paraffin-embedded surgical specimens</measure>
    <time_frame>Specimens were obtained within 28 days prior to the start of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alvespimycin</intervention_name>
    <description>Solution, IV, Alvespimycin 80 mg/m2, Weekly one hour infusion Days 1, 8, and 15, every 4 weeks thereafter until disease progression or DLT</description>
    <arm_group_label>A1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  KPS performance status of &gt;= 80% (&quot;normal activity with effort&quot;)

          -  Metastatic breast cancer with Her2 amplification by FISH or 3+ Her2 overexpression by
             immunohistochemistry (&quot;IHC&quot;)

          -  Must have received no more than one prior cytotoxic chemotherapy regimen in the
             metastatic setting

          -  Measurable disease by RECIST Criteria

        Exclusion Criteria:

          -  Received prior lapatinib, an investigational ErbB-2 and/or an investigational EGFR
             dual tyrosine kinase inhibitors

          -  Administration of any other chemotherapy, biological, immunotherapy or investigational
             agent within 14 days prior to receipt of study medication

          -  Pregnant or breast-feeding women. Known CNS metastases, unless treated and without
             clinically significant neurological deficits

          -  Moderately severe dry eye

          -  Congestive heart failure, or a left ventricular ejection fraction

          -  Myocardial infarction or active ischemic heart disease within 12 months prior to study
             drug administration

          -  Previous malignancies unless free of recurrence for at least 5 years
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2008</study_first_submitted>
  <study_first_submitted_qc>October 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2008</study_first_posted>
  <disposition_first_submitted>September 10, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>September 10, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 14, 2010</disposition_first_posted>
  <last_update_submitted>October 12, 2015</last_update_submitted>
  <last_update_submitted_qc>October 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

